ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key Stats

• Today's Range: $0.68 to $0.78
• 50-Day Range: $0.51 to $1.08
• 52-Week Range: $0.46 to $4.44
• Volume: 463,145 shs
• Average Volume: 689,948 shs
• Market Capitalization: $211.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 33% of companies evaluated by MarketBeat, and ranked 753rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ProKidney has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProKidney are expected to grow in the coming year, from ($0.57) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.50% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 11.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.50% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 11.32%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for ProKidney this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added ProKidney to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,175,419.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROK Stock Analysis - Frequently Asked Questions

How have PROK shares performed this year?

ProKidney's stock was trading at $1.69 at the beginning of 2025. Since then, PROK stock has decreased by 57.3% and is now trading at $0.7214.
View the best growth stocks for 2025 here.

How were ProKidney's earnings last quarter?

ProKidney Corp. (NASDAQ:PROK) issued its quarterly earnings results on Monday, March, 17th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.03. The company had revenue of $0.08 million for the quarter.

Who are ProKidney's major shareholders?

ProKidney's top institutional investors include Hennion & Walsh Asset Management Inc. (0.29%) and Bank of New York Mellon Corp (0.08%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber.
View institutional ownership trends.

How do I buy shares of ProKidney?

Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProKidney own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +626.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -10.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.08
• Quick Ratio: 17.09

Sales & Book Value

• Annual Sales: $76,000.00
• Price / Sales: 2,652.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.84) per share
• Price / Book: -0.14

Miscellaneous

• Outstanding Shares: 292,698,000
• Free Float: 170,651,000
• Market Cap: $201.55 million
• Optionable: Optionable
• Beta: 1.50